Department of Infectious Diseases, Hospital Clinic - IDIBAPS, University of Barcelona, Villarroel 170, 08036, Barcelona, Spain.
Kidney Transplant Unit, Hospital Clinic - IDIBAPS, University of Barcelona, Barcelona, Spain.
BMC Nephrol. 2019 Jul 22;20(1):274. doi: 10.1186/s12882-019-1461-4.
In recent years we have witnessed an increase in infections due to multidrug-resistant organisms in kidney transplant recipients (KTR). In our setting, we have observed a dramatic increase in infections caused by extended-spectrum betalactamase-producing (ESBL) Enterobacteriaceae in KTR. In 2014 we changed surgical prophylaxis from Cefazolin 2 g to Ertapenem 1 g.
We compared bacterial infections and their resistance phenotype during the first post-transplant month with an historical cohort collected during 2013 that had received Cefazolin.
During the study period 110 patients received prophylaxis with Cefazolin and 113 with Ertapenem. In the Ertapenem cohort we observed a non-statistically significant decrease in the percentage of early bacterial infection from 57 to 47%, with urine being the most frequent source in both. The frequency of infections caused by Enterobacteriaceae spp. decreased from 64% in the Cefazolin cohort to 36% in the Ertapenem cohort (p = 0.005). In addition, percentage of ESBL-producing strains decreased from 21 to 8% of all Enterobacteriaceae isolated (p = 0.015). After adjusted in multivariate Cox regression analysis, male sex (HR 0.16, 95%CI: 0.03-0.75), cefazolin prophylaxis (HR 4.7, 95% CI: 1.1-22.6) and acute rejection (HR 14.5, 95% CI: 1.3-162) were associated to ESBL- producing Enterobacteriaceae infection.
Perioperative antimicrobial prophylaxis with a single dose of Ertapenem in kidney transplant recipients reduced the incidence of early infections due to ESBL-producing Enterobacteriaceae without increasing the incidence of other multidrug-resistant microorganisms or C. difficile.
近年来,肾移植受者(KTR)中多重耐药菌感染有所增加。在我们的环境中,KTR 中由产超广谱β-内酰胺酶(ESBL)肠杆菌科引起的感染急剧增加。2014 年,我们将手术预防用抗生素从头孢唑林 2g 改为厄他培南 1g。
我们比较了接受头孢唑林和厄他培南预防治疗的 KTR 在移植后第一个月的细菌感染及其耐药表型。
在研究期间,110 例患者接受头孢唑林预防治疗,113 例患者接受厄他培南预防治疗。在厄他培南组中,我们观察到早期细菌感染的百分比从 57%降至 47%,但尿液仍是两种情况下最常见的感染源。肠杆菌科感染的频率从头孢唑林组的 64%降至厄他培南组的 36%(p=0.005)。此外,产 ESBL 菌株的比例从头孢唑林组的 21%降至厄他培南组的 8%(p=0.015)。在多变量 Cox 回归分析中,男性(HR 0.16,95%CI:0.03-0.75)、头孢唑林预防(HR 4.7,95%CI:1.1-22.6)和急性排斥反应(HR 14.5,95%CI:1.3-162)与产 ESBL 肠杆菌科感染相关。
在肾移植受者中单次使用厄他培南进行围手术期抗菌预防可降低产 ESBL 肠杆菌科引起的早期感染发生率,而不会增加其他多药耐药微生物或艰难梭菌的感染发生率。